Validate Cryopreservation As A Defined Input, Not A Variable

Cryopreservation plays a critical role in advanced therapy development, yet it is often treated as an assumed step rather than a defined, controlled process. This piece explores why that mindset introduces unnecessary risk. Variability in freezing methods, materials, handling, and storage conditions can directly affect cell viability, potency, and overall therapy performance. The discussion reframes cryopreservation as a validated input—one that should be standardized, measured, and aligned with regulatory expectations from early development through commercialization. Emphasis is placed on process control, reproducibility, and documentation, especially as therapies scale and move across multiple sites. By defining cryopreservation parameters upfront and managing them with the same rigor as other critical inputs, organizations can reduce batch-to-batch variability and improve confidence in clinical and commercial outcomes. For teams working to strengthen product integrity and de-risk development timelines, this perspective highlights why cryopreservation deserves deliberate design, not assumptions.